Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.

The specification relates to osimertinib or a pharmaceutically acceptable salt thereof for use in the treatment of patients with locally advanced unresectable epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (Stage III)), and in particular to the treatment of patients whose disease has not progressed following definitive platinum-based chemoradiation therapy.

The specification relates to osimertinib or a pharmaceutically acceptable salt thereof for use in the treatment of patients with locally advanced unresectable epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (Stage III)), and in particular to the treatment of patients whose disease has not progressed following definitive platinum-based chemoradiation therapy.

Gallium-salophen compounds, and methods of using the same for the treatment of disease are disclosed.

Pharmaceutical compositions containing tetrathiomolybdate (TTM) are disclosed. Pharmaceutical compositions and formulations that contain TTM along with other co-drugs, such as diethylcarbamazine (DEC) and astaxanthin (ATX), are also disclosed. Formulations include a delayed release oral form that releases the TTM in the gastrointestinal tract after the oral form passes the stomach, and an enteric oral form that is not a delayed release form are disclosed. Methods of treating cancer, treating cancer patients as an adjuvant therapy, and treating pulmonary arterial hypertension by administering the pharmaceutical compositions are further disclosed.

Pharmaceutical compositions containing tetrathiomolybdate (TTM) are disclosed. Pharmaceutical compositions and formulations that contain TTM along with other co-drugs, such as diethylcarbamazine (DEC) and astaxanthin (ATX), are also disclosed. Formulations include a delayed release oral form that releases the TTM in the gastrointestinal tract after the oral form passes the stomach, and an enteric oral form that is not a delayed release form are disclosed. Methods of treating cancer, treating cancer patients as an adjuvant therapy, and treating pulmonary arterial hypertension by administering the pharmaceutical compositions are further disclosed.

A solid form formulation comprising chromium (sucrosomial chromium®) or copper (sucrosomial copper®) or a vitamin (sucrosomial vitamin®) and related composition, process for the preparation and method for treatment of a chromium deficiency and/or a change in the carbohydrate metabolism and/or a change in the muscle energy metabolism are described.

A solid form formulation comprising chromium (sucrosomial chromium®) or copper (sucrosomial copper®) or a vitamin (sucrosomial vitamin®) and related composition, process for the preparation and method for treatment of a chromium deficiency and/or a change in the carbohydrate metabolism and/or a change in the muscle energy metabolism are described.

A solid form formulation based on a nutrient comprising: (a) a mineral or a vitamin, (b) a phospholipid, (c) a first agent selected from (c-i) carrageenan and (c-ii) acacia gum, and, optionally, (d) a sucrester and/or (e) a starch of plant origin and related composition, process of preparation and method of treatment of a deficiency of said mineral and/or vitamin are disclosed.

A solid form formulation based on a nutrient comprising: (a) a mineral or a vitamin, (b) a phospholipid, (c) a first agent selected from (c-i) carrageenan and (c-ii) acacia gum, and, optionally, (d) a sucrester and/or (e) a starch of plant origin and related composition, process of preparation and method of treatment of a deficiency of said mineral and/or vitamin are disclosed.